Promising combo targets Hard-to-Treat head and neck cancer
NCT ID NCT04862650
First seen Feb 15, 2026 · Last updated Jun 10, 2026 · Updated 19 times
Summary
This study tests a combination of an immunotherapy drug (cemiplimab) and two low-dose chemotherapy drugs (paclitaxel and carboplatin) in people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than standard treatments. About 46 adults who have not had prior systemic therapy for advanced disease are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.